vs
Side-by-side financial comparison of Purple Innovation, Inc. (PRPL) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Purple Innovation, Inc. is the larger business by last-quarter revenue ($140.7M vs $129.7M, roughly 1.1× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 9.1%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 8.3%).
Purple Carrot is a Needham, Massachusetts-based, and 100% plant-based meal kit company. Founded by Andy Levitt, it offers both prepared meals as well as meal kits to subscribers weekly. As stated in a 2022 article in Cosmopolitan, “each Purple Carrot meal kit results in 72% less carbon being released into the atmosphere as compared to the standard American meal.”
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
PRPL vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $140.7M | $129.7M |
| Net Profit | $-3.2M | — |
| Gross Margin | 41.9% | 98.0% |
| Operating Margin | -1.6% | -25.0% |
| Net Margin | -2.3% | — |
| Revenue YoY | 9.1% | 73.4% |
| Net Profit YoY | 62.1% | — |
| EPS (diluted) | $0.03 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $140.7M | $129.7M | ||
| Q3 25 | $118.8M | $164.9M | ||
| Q2 25 | $105.1M | $114.4M | ||
| Q1 25 | $104.2M | $81.7M | ||
| Q4 24 | $129.0M | $74.8M | ||
| Q3 24 | $118.6M | $62.9M | ||
| Q2 24 | $120.3M | $54.1M | ||
| Q1 24 | $120.0M | $41.4M |
| Q4 25 | $-3.2M | — | ||
| Q3 25 | $-11.7M | $25.7M | ||
| Q2 25 | $-17.3M | $-12.8M | ||
| Q1 25 | $-19.1M | $-41.2M | ||
| Q4 24 | $-8.5M | — | ||
| Q3 24 | $-39.2M | $-54.8M | ||
| Q2 24 | $27.0K | $-70.4M | ||
| Q1 24 | $-50.2M | $-136.1M |
| Q4 25 | 41.9% | 98.0% | ||
| Q3 25 | 42.8% | 99.0% | ||
| Q2 25 | 35.9% | 98.7% | ||
| Q1 25 | 39.4% | 94.3% | ||
| Q4 24 | 42.9% | 96.6% | ||
| Q3 24 | 29.7% | 97.4% | ||
| Q2 24 | 40.7% | 96.2% | ||
| Q1 24 | 34.8% | 96.4% |
| Q4 25 | -1.6% | -25.0% | ||
| Q3 25 | -10.2% | 15.1% | ||
| Q2 25 | -13.5% | -11.1% | ||
| Q1 25 | -13.9% | -52.2% | ||
| Q4 24 | -6.0% | -81.2% | ||
| Q3 24 | -39.5% | -89.3% | ||
| Q2 24 | -12.1% | -125.1% | ||
| Q1 24 | -19.3% | -336.5% |
| Q4 25 | -2.3% | — | ||
| Q3 25 | -9.9% | 15.6% | ||
| Q2 25 | -16.5% | -11.1% | ||
| Q1 25 | -18.4% | -50.4% | ||
| Q4 24 | -6.6% | — | ||
| Q3 24 | -33.1% | -87.1% | ||
| Q2 24 | 0.0% | -130.1% | ||
| Q1 24 | -41.8% | -328.9% |
| Q4 25 | $0.03 | $0.04 | ||
| Q3 25 | $0.11 | $0.28 | ||
| Q2 25 | $0.16 | $-0.14 | ||
| Q1 25 | $0.18 | $-0.47 | ||
| Q4 24 | $0.08 | $-0.71 | ||
| Q3 24 | $0.36 | $-0.70 | ||
| Q2 24 | $0.00 | $-0.91 | ||
| Q1 24 | $0.47 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.3M | $93.0M |
| Total DebtLower is stronger | $126.7M | — |
| Stockholders' EquityBook value | $-29.7M | $114.8M |
| Total Assets | $296.3M | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.3M | $93.0M | ||
| Q3 25 | $32.4M | $110.9M | ||
| Q2 25 | $34.2M | $75.2M | ||
| Q1 25 | $21.6M | $61.9M | ||
| Q4 24 | $29.0M | $58.5M | ||
| Q3 24 | $23.4M | $36.4M | ||
| Q2 24 | $23.4M | $32.3M | ||
| Q1 24 | $34.5M | $43.3M |
| Q4 25 | $126.7M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $70.7M | — | ||
| Q3 24 | $50.8M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-29.7M | $114.8M | ||
| Q3 25 | $-26.9M | $73.6M | ||
| Q2 25 | $-15.6M | $32.7M | ||
| Q1 25 | $1.3M | $32.8M | ||
| Q4 24 | $20.2M | $59.1M | ||
| Q3 24 | $28.0M | $-30.5M | ||
| Q2 24 | $66.4M | $15.1M | ||
| Q1 24 | $65.5M | $74.1M |
| Q4 25 | $296.3M | $605.2M | ||
| Q3 25 | $302.1M | $538.6M | ||
| Q2 25 | $303.8M | $555.3M | ||
| Q1 25 | $293.8M | $548.8M | ||
| Q4 24 | $307.8M | $594.1M | ||
| Q3 24 | $309.3M | $504.4M | ||
| Q2 24 | $362.1M | $551.1M | ||
| Q1 24 | $382.1M | $663.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.50× | — | ||
| Q3 24 | 1.82× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.8M | $60.7M |
| Free Cash FlowOCF − Capex | $-7.8M | — |
| FCF MarginFCF / Revenue | -5.5% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-41.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.8M | $60.7M | ||
| Q3 25 | $-968.0K | $14.3M | ||
| Q2 25 | $-4.0M | $5.0M | ||
| Q1 25 | $-23.1M | $-42.2M | ||
| Q4 24 | $6.8M | $-35.7M | ||
| Q3 24 | $1.1M | $-42.5M | ||
| Q2 24 | $-8.9M | $-40.2M | ||
| Q1 24 | $-16.8M | $-119.0M |
| Q4 25 | $-7.8M | — | ||
| Q3 25 | $-1.8M | $14.2M | ||
| Q2 25 | $-7.0M | — | ||
| Q1 25 | $-25.3M | — | ||
| Q4 24 | $5.7M | — | ||
| Q3 24 | $101.0K | — | ||
| Q2 24 | $-11.0M | $-40.3M | ||
| Q1 24 | $-19.9M | — |
| Q4 25 | -5.5% | — | ||
| Q3 25 | -1.5% | 8.6% | ||
| Q2 25 | -6.6% | — | ||
| Q1 25 | -24.3% | — | ||
| Q4 24 | 4.4% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | -9.2% | -74.5% | ||
| Q1 24 | -16.5% | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 0.7% | 0.1% | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | 0.9% | 0.0% | ||
| Q2 24 | 1.7% | 0.2% | ||
| Q1 24 | 2.5% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -330.22× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
